Portage Biotech Inc. (PRTG) Financials
This page shows Portage Biotech Inc. (PRTG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Portage Biotech Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
For every $1 of reported earnings, Portage Biotech Inc. used $0.01 of operating cash (-$1.1M OCF vs $123.7M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2018.
Cash & Balance Sheet
Portage Biotech Inc. held $7.5M in cash as of Q4 2018; long-term debt is not reported for that period.
Not reported for Q4 2018.
Not reported for Q4 2018.
Margins & Returns
None of these metrics is reported for Q4 2018.
Capital Allocation
None of these metrics is reported for Q4 2018.
PRTG Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'18 | Q4'17 |
|---|
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
PRTG Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'18 | Q4'17 |
|---|---|---|
| Current Assets | $7.6M-87.1% | $59.1M |
| Cash & Equivalents | $7.5M+4629.6% | $159K |
| Current Liabilities | $127K+16.5% | $109K |
| Non-Current Liabilities | $257K+27.9% | $201K |
| Total Equity | $9.6M-83.9% | $59.6M |
| Retained Earnings | -$14.3M-195.7% | $15.0M |
Not reported in any period shown, so not listed: Total Assets, Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Total Liabilities, Long-Term Debt.
PRTG Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'18 | Q4'17 |
|---|
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
PRTG Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'18 | Q4'17 |
|---|---|---|
| Current Ratio | 59.97-482.6x | 542.53 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Portage Biotech Inc. PRTG | FY2018 | N/A | $123.7M | N/A | $15.5M | — |
| MetaVia Inc. MTVA | FY2025 | N/A | -$13.0M | N/A | $10.1M | — |
| NextCure, Inc. NXTC | FY2025 | N/A | -$55.8M | N/A | $22.7M | — |
| Briacell Therapeutics Corp. BCTX | FY2025 | N/A | -$26.3M | N/A | $35.8M | — |
| NovaBay Pharmaceuticals, Inc. NBY | FY2025 | N/A | N/A | N/A | $51.9M | — |
| BioLineRX Ltd BLRX | FY2025 | $1.2M | -$2.0M | N/A | $11.7M | 17/100 |
Where Portage Biotech Inc. Ranks
Frequently Asked Questions
Is Portage Biotech Inc. profitable?
Yes, Portage Biotech Inc. (PRTG) reported a net income of $123.7M in fiscal year 2018.
What is Portage Biotech Inc.'s return on equity (ROE)?
Portage Biotech Inc. (PRTG) has a return on equity of 1286.4% for fiscal year 2018, measuring how efficiently the company generates profit from shareholder equity.
What is Portage Biotech Inc.'s operating cash flow?
Portage Biotech Inc. (PRTG) recorded an outflow of $1.1M in operating cash flow during fiscal year 2018, representing cash used by core business activities.
What is Portage Biotech Inc.'s current ratio?
Portage Biotech Inc. (PRTG) had a current ratio of 59.97 as of fiscal year 2018, which is generally considered healthy.
Are Portage Biotech Inc.'s earnings high quality?
For every $1 of reported earnings, Portage Biotech Inc. (PRTG) used $0.01 of operating cash (-$1.1M OCF vs $123.7M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.